TY - JOUR
T1 - Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
AU - Andrade, Fernanda
AU - Rafael, Diana
AU - Videira, Mafalda
AU - Ferreira, Domingos
AU - Sosnik, Alejandro
AU - Sarmento, Bruno
N1 - Funding Information:
Fernanda Andrade gratefully acknowledges the Fundação para a Ciência e a Tecnologia (FCT) , Portugal, for financial support ( SFRH/BD/73062/2010 ). FA, DF, AS and BS thank the FCT (Portugal)/Ministry of Science, Technology and Innovation (MINCyT, Argentina) exchange program granted for the period 2010–2011. There is no potential conflict of interest to be reported.
PY - 2013
Y1 - 2013
N2 - Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations.Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic.Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
AB - Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations.Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic.Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
KW - Drug resistance
KW - Inhalation
KW - Nanoparticles
KW - Respiratory infections
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=84888198111&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2013.07.020
DO - 10.1016/j.addr.2013.07.020
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:84888198111
SN - 0169-409X
VL - 65
SP - 1816
EP - 1827
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 13-14
ER -
